A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• •1. The patient volunteered to participate in the study and signed the Informed Consent;
• •2. Age, 18-70 years (include 18 and 70), male or female;
• •3. Expected survival ≥ 12 weeks
• •4. Eastern Cooperative Oncology Group score 0-2
• •5. CD19 or CD20 positive B-Non-Hodgkin's lymphoma confirmed by cytology or histology according to World Health Organization 2016 criteria;
• •6. Patients with a clear diagnosis of relapsed and/or refractory B-Non-Hodgkin's lymphoma, including Diffuse Large B Cell Lymphoma, Follicular Lymphoma and Mantle Cell Lymphoma. Diffuse Large B Cell Lymphoma includes the following types:
• •1. Diffuse Large B Cell Lymphoma, Non Specifically
• •2. Primary Mediastinal B-cell Lymphoma
• •3. Transformed Follicular Lymphoma
• •4. High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6
• •5. High Grade B-Cell Lymphoma, Non Specifically
• •7. For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause of intolerance should be recorded;
• •8. No contraindications of apheresis.
• •9. At least one measurable lesion according to Lugano 2014 criteria;
• •10. Adequate organ function and adequate bone marrow reserve
• •1. Hemoglobin≥80 g/L
• •2. Absolute neutrophil count≥1.0×109/L
• •3. Platelet≥50×109/L,
• •4. Creatinine≤1.5×upper limit of the normal range (ULN)
• •5. Cardiac ejection fraction≥50%
• •6. Saturation of Pulse Oxygen\>92%
• •7. Total bilirubin≤1.5×ULN
• •8. Alanine Aminotransferase/Aspartate Aminotransferase≤3×ULN